Gemphire Therapeutics Inc. (GEMP) Given Consensus Recommendation of “Buy” by Analysts
Gemphire Therapeutics Inc. (NASDAQ:GEMP) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $24.60.
GEMP has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Thursday, November 16th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective (up from $21.00) on shares of Gemphire Therapeutics in a report on Tuesday, November 14th. Canaccord Genuity set a $31.00 price objective on shares of Gemphire Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Roth Capital initiated coverage on shares of Gemphire Therapeutics in a report on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective on the stock.
Gemphire Therapeutics (NASDAQ GEMP) traded down $0.09 during midday trading on Friday, reaching $7.77. 32,900 shares of the company’s stock traded hands, compared to its average volume of 64,932. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bamco Inc. NY purchased a new stake in shares of Gemphire Therapeutics during the third quarter valued at $2,709,000. Cambridge Investment Research Advisors Inc. lifted its position in Gemphire Therapeutics by 4.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock valued at $1,520,000 after purchasing an additional 6,900 shares during the period. Comerica Bank acquired a new position in Gemphire Therapeutics during the third quarter valued at $850,000. Northpointe Capital LLC lifted its position in Gemphire Therapeutics by 91.8% during the third quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after purchasing an additional 249,077 shares during the period. Finally, Advisory Services Network LLC acquired a new position in Gemphire Therapeutics during the second quarter valued at $139,000. 32.11% of the stock is currently owned by hedge funds and other institutional investors.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.